ArticleThe journal of sexual medicine2023
Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events.
Federico Belladelli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it